June 17, 2020 07:27 AM EDT

All in on IL-11, Frazier unveils latest startup with dual focus on fibrosis and cancer

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges